Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 3Thoracic 1Lymphoid 1Head & Neck 1Gynecologic 1Gastrointestinal 1Dermatologic 1

Conditions

Squamous Cell Carcinoma of Head and Neck 8Head and Neck Neoplasms 8Melanoma 5Parkinson Disease 4, Autosomal Dominant Lewy Body 3Ovarian Neoplasms 3Lung Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Small Cell Lung Carcinoma 2Lymphoma 2Endometrial Neoplasms 2Colorectal Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Renal Cell 2Carcinoma, Hepatocellular 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Microsatellite Instability 1Mesothelioma 1Glioblastoma 1Esophageal Neoplasms 1Carcinoma, Merkel Cell 1

Interventions

Nivolumab 4regorafenib 2pembrolizumab 2Drug Therapy 2Cisplatin 2vocimagene amiretrorepvec 1ulixertinib 1spartalizumab 1motexafin gadolinium 1erythromycin propionate-N-acetylcysteinate 1epacadostat 1durvalumab 1depatuxizumab mafodotin 1cobimetinib 1cc-486 1aflibercept 1Thalidomide 1Tamoxifen 1Radiotherapy 1Quality of Life 1Patient Reported Outcome Measures 1Paclitaxel 1NEO212 1Molecular Diagnostic Techniques 1Ipilimumab 1Injections 1Immunotherapy 1IFL protocol 1Gemcitabine 1Fluorodeoxyglucose F18 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioblastoma × epacadostat × Head & Neck × Clear all
NCT02327078 2025-08-14

A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)

Incyte Corporation

Phase 1/2 Completed
307 enrolled 27 charts
CNSDermatologicGastrointestinalGynecologicHead & NeckLymphoidThoracic

Glioblastoma, Head and Neck Neoplasms, Lung Neoplasms, Lymphoma, Melanoma, Ovarian Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡